[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603381":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: patients received L-AmB therapy",null,"Dose: 3-5mg\u002Fkg\u002Fday administered intravenouly(IV). Duration of treatment: Researchers determine based on the severity of the underlying disease, the recovery of immune suppression, and clinical response.\n\nAll drug dosages are in accordance with the drug instructions.All treatments must be prescribed according to local routine clinical practice, and the preparation and administration of drugs must be carried out in accordance with the instructions and guidelines provided by the manufacturer.",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2: patients received isavuconazole\u002Fposaconzazole therapy","Foumulations: Oral tablets or intravenous (IV) formulations. Dosing: Loading dose: As per product labeling. Maintenance dose: 300mg (posaconzazole) or 200mg (isavuconazole) once daily. Duration of treatment: Researchers determine based on the severity of the underlying disease, the recovery of immune suppression, and clinical response.\n\nAll drug dosages are in accordance with the drug instructions. All treatments must be prescribed according to local routine clinical practice, and the preparation and administration of drugs must be carried out in accordance with the instructions and guidelines provided by the manufacturer.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"erlie jiang, doctor","CONTACT","02223608600","jiangerlie@ihcams.ac.cn",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":31,"coordinates":32},"Point",[33,34],117.17667,39.14222,{"lat":34,"lon":33},[37],{"name":38,"role":18,"phone":19,"phoneExt":10,"email":39},"erlie jiang, Doctor","jiangerlie@ihacams.ac.cn",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100603381","liposomal-amphotericin-b-and-isavuconazoleposaconazole-in-br-ifd-breakthrough-invasive-fungal-disease-in-patients-with-malignant-hematological-diseases-100603381",false,"NCT07135778","Liposomal Amphotericin B and Isavuconazole\u002FPosaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases","The Efficacy and Safety of Liposomal Amphotericin B and Isavuconazole\u002FPosaconazole in the Treatment of Breakthrough Invasive Fungal Disease in Patients With Malignant Hematological Diseases After Antifungal Prophylaxis","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years at the beginning of treatment.\n* The patient or their guardian must be able to understand and sign a written informed consent form (which must be obtained before starting any research procedure)\n* Blood based diseases, mainly AML( Acute Myeloid Leukemia), ALL(Acute Lymphoblastic Leukemia), MDS(Myelodysplastic Syndromes)\n* Breakthrough invasive fungal disease occurs after receiving antifungal prophylaxis with triazole drugs for ≥ 7 days\n* According to the latest definition of MSGERC, breakthrough IFD is defined as any IFD that occurs during exposure to antifungal drugs, including fungal infections outside the spectrum of antifungal activity\n* Proven, probable, and possible IFD in accordance with the\\\u003C The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision) \\>\n\nExclusion Criteria:\n\n* Confirmed patients with allergies\u002Frapid onset severe allergic reactions\u002Fintolerance to L-AmB or isavuconazole \u002Fposaconazole\n* Serum creatinine level ≥ 2 times the upper limit of normal\n* The level of transaminase or alkaline phosphatase is ≥ 5 times the normal upper limit, and bilirubin is ≥ 3 times the normal upper limit\n* Patients who are breastfeeding\n* Pregnant patients\n* Expected life expectancy is less than 30 days\n* Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.","ALL","18 Years",{"count":52,"type":53},36,"ESTIMATED","OBSERVATIONAL","This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days of echinocandin or triazole antifungal prophylaxis receive treatment with liposomal amphotericin B or treatment with Isavuconazole or posaconazole according to the clinical doctor's decision. It is planed to collect 36 patients receiving treatment with liposomal amphotericin B and 36 patients receiving treatment with Isavuconazole or posaconazole, and observe their efficacy and safety.",[57],"Invasive Fungal Disease","2025-08-20",{"date":60,"type":61},"2025-08-22","ACTUAL",{"date":63,"type":61},"2025-05-19",{"date":65,"type":53},"2026-12-31",{"name":5,"class":6},1]